FDA approved the use of PD-1/PD-L1 immunotherapies for patients with malignant melanoma, including pembrolizumab, nivolumab, and atezolizumab, without specific CDx regimen for melanoma patients. The gene discussed is PDCD1; the disease is melanoma.